{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:57:45Z","timestamp":1791446265081,"version":"4.3.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICIs) rechallenge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a nationwide retrospective study between April 2018 and March 2020 including irM without myocardial involvement. Depending on the presence of cutaneous signs or unusual histopathological features, patients were classified into two groups: typical or atypical irM. Therapeutic strategies were analysed in both groups. The modalities and outcomes of ICI rechallenge were reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 20 patients, 16 presented typical irM. Regardless of severity, most typical irM were treated with steroid monotherapy (n\u2009=\u200914\/16) and all had a complete response within \u22643\u2009weeks. The efficacy of oral steroids for non-severe typical irM (n\u2009=\u200910) was the same with low-dose (\u22640.5\u2009mg\/kg\/day) or high-dose (1\u2009mg\/kg\/day). Severe typical irM were successfully treated with intravenous methylprednisolone. Atypical irM (n\u2009=\u20094) had a less favourable evolution, including one irM-related death, and required heavy immunosuppression. ICIs were safely reintroduced in nine patients presenting a moderate (n\u2009=\u20096) or a severe (n\u2009=\u20093) irM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favour of a safe reintroduction of ICI following symptom resolution and creatin kinase (CK) normalization in moderate and severe forms of irM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab249","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T12:19:27Z","timestamp":1615465167000},"page":"5753-5764","source":"Crossref","is-referenced-by-count":28,"title":["Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study"],"prefix":"10.1093","volume":"60","author":[{"given":"Amandine","family":"Weill","sequence":"first","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Bichat, Universit\u00e9 de Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Delyon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Saint Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Descamps","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Bichat, Universit\u00e9 de Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Deschamps","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Bichat, AP-HP, Universit\u00e9 de Paris, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Dinulescu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU de Rennes, Universit\u00e9 de Rennes, Rennes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU de Rennes, Universit\u00e9 de Rennes, Rennes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"C\u00e9l\u00e9rier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CH de La Rochelle, La Rochelle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlee","family":"Nardin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU de Besan\u00e7on, Universit\u00e9 de Franche Comt\u00e9, Besan\u00e7on"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Aubin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU de Besan\u00e7on, Universit\u00e9 de Franche Comt\u00e9, Besan\u00e7on"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU d\u2019Angers, Universit\u00e9 LUNAM, Angers"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Heidelberger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Avicenne, AP-HP, Universit\u00e9 Sorbonne Paris Nord, Bobigny"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital La Timone, AP-HM, Universit\u00e9 d\u2019Aix-Marseille, Marseille"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausicaa","family":"Malissen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Ambroise-Par\u00e9, AP-HP, Boulogne-Billancourt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Longvert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Ambroise-Par\u00e9, AP-HP, Boulogne-Billancourt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Machet","sequence":"additional","affiliation":[{"name":"Dermatology Department, CHRU de Tours, Universit\u00e9 de Tours, Tours"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, H\u00f4pital Bichat, AP-HP, Universit\u00e9 de Paris, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenne","family":"Brosseau","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, H\u00f4pital Bichat, AP-HP, Universit\u00e9 de Paris, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertille","family":"Bonniaud","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Universitaire de Dijon, Dijon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Jeudy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Universitaire de Dijon, Dijon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[{"name":"Department of Neurology, H\u00f4pital La Piti\u00e9 Salp\u00e9tri\u00e8re, AP-HP, Universit\u00e9 Sorbonne Paris Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Doucet","sequence":"additional","affiliation":[{"name":"Department of Oncology, H\u00f4pital Saint Louis, AP-HP, Universit\u00e9 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebbe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Saint Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, H\u00f4pital Bichat, AP-HP, Universit\u00e9 de Paris, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"De Masson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Saint Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barouyr","family":"Baroudjian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Saint Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leonard-Louis","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, H\u00f4pital La Piti\u00e9 Salp\u00e9tri\u00e8re, AP-HP, Universit\u00e9 Sorbonne Paris Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Hervier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Saint Louis, AP-HP, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2100-2913","authenticated-orcid":false,"given":"Florence","family":"Brunet-Possenti","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Bichat, Universit\u00e9 de Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"2021121823182001100_keab249-B1","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021121823182001100_keab249-B2","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"2021121823182001100_keab249-B3","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2021121823182001100_keab249-B4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2021121823182001100_keab249-B5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021121823182001100_keab249-B6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021121823182001100_keab249-B7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2021121823182001100_keab249-B8","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO\u2019s adverse drug reactions database","author":"Nguy\u1ec5n","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021121823182001100_keab249-B9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CCO.0000000000000610","article-title":"Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting","volume":"32","author":"Herrscher","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"2021121823182001100_keab249-B10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021121823182001100_keab249-B11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"2021121823182001100_keab249-B12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2021121823182001100_keab249-B13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2021121823182001100_keab249-B14","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"2021121823182001100_keab249-B15","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"2021121823182001100_keab249-B16","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021121823182001100_keab249-B17","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1136\/annrheumdis-2018-214336","article-title":"Immune checkpoint inhibitor rechallenge in patients with immune-related myositis","volume":"78","author":"Delyon","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021121823182001100_keab249-B18","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.1016\/j.annder.2016.09.575","article-title":"Dermatomyosite retard\u00e9e et fatale sous anti-PD1 malgr\u00e9 une r\u00e9ponse compl\u00e8te\u202f: une nouvelle complication des anti-PD1","volume":"143","author":"Malissen","year":"2016","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"key":"2021121823182001100_keab249-B19","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"2021121823182001100_keab249-B20","doi-asserted-by":"crossref","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2021121823182001100_keab249-B21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"2021121823182001100_keab249-B22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"key":"2021121823182001100_keab249-B23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13760-020-01282-w","article-title":"Myositis as a neuromuscular complication of immune checkpoint inhibitors","volume":"120","author":"Vermeulen","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"2021121823182001100_keab249-B24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 Inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"2021121823182001100_keab249-B25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"2021121823182001100_keab249-B26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"2021121823182001100_keab249-B27","doi-asserted-by":"crossref","first-page":"e139\u201345","DOI":"10.1111\/ajco.13177","article-title":"Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy","volume":"16","author":"Burdett","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"2021121823182001100_keab249-B28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"2021121823182001100_keab249-B29","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021121823182001100_keab249-B30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab249\/37179360\/keab249.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/12\/5753\/41820466\/keab249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/12\/5753\/41820466\/keab249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:27:18Z","timestamp":1639870038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/12\/5753\/6174125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,3,16]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab249","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,3,16]]}}}